U.S. approves “milestone” Parkinson’s treatment for 2025 release
The treatment, which will be sold under the name Onapgo, is essentially a subcutaneous – under the skin – device that allows for continuous infusion of the dopamine agonist apomorphine hydrochloride to reduce ‘off’ episodes. These episodes are periods during the day and night when lepodova medication wears off and adverse motor-function symptoms become amplified. In trial, Onapgo significantly reduced these daily off episodes by an average of 2.47 hours, compared to the placebo treatment.